Five-year outcomes from neoadjuvant, adjuvant, and perioperative immunotherapy trials in resectable NSCLC clarify which patients benefit most.
|Videos|November 3, 2017
Dr. Lam Discusses Agents for ROS1-Mutated NSCLC
Author(s)Vincent Lam, MD
Vincent Lam, MD, assistant professor, The University of Texas MD Anderson Cancer, discusses agents to target ROS1-mutated non-small cell lung cancer (NSCLC).
Advertisement
Vincent Lam, MD, assistant professor, The University of Texas MD Anderson Cancer, discusses agents to target ROS1-mutated non-small cell lung cancer (NSCLC).
The agent that is furthest in development is lorlatinib which was investigated in a phase II trial. The ROS1 cohort demonstrated good response for patients who had been previously treated or were treatment-na
Advertisement
Related to this article
Sanja Dacic, MD, PhD, outlines advances that are reshaping molecular profiling in advanced non–small cell lung cancer and how to navigate these changes.
Solange Peters, MD, PhD, outlines why docetaxel still anchors second-line therapy in NSCLC and where biomarker retesting could move the field.
The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
Marina Chiara Garassino, MD, provided a review of AI-designed drugs, autonomous clinical agents, and prescreening devices.
The top 5 OncLive TV videos of the week cover insights in pancreatic cancer, non–small cell lung cancer, the cost and value of immunotherapy, and bladder cancer.
The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.
New data on multiple targeted agents and evolving diagnostic frameworks highlight progress in classifying and treating EGFR PACC–mutated NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Finalizes 3 Guidance Documents to Broaden Cancer Clinical Trial Eligibility Criteria
2
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
3
Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma
4
HR-Positive/HER2-Negative Metastatic Breast Cancer: Treatment Sequencing After Adjuvant Endocrine Therapy and Transitioning Beyond Endocrine-Based Approaches
5